Abstract
In the process of drug development, there has been an exceptionally high attrition rate in oncological compounds entering late phases of testing. This has seen a concurrent reduction in approved NCEs (new chemical entities) reaching patients. Network pharmacology has become a valuable tool in understanding the fine details of drug-target interactions as well as painting a more practical picture of phenotype relationships to patients and drugs. By utilizing all the tools achieved through molecular medicine and combining it with high throughput data analysis, interactions and mechanisms can be elucidated and treatments reasonably tailored to patients expressing specific phenotypes (or genotypes) of disease, essentially reigning in the phenomenon of drug attrition.
Keywords: Network pharmacology, drug attrition, systems biology, network medicine
Current Drug Discovery Technologies
Title:Network Pharmacology: Reigning in Drug Attrition?
Volume: 10 Issue: 2
Author(s): Osama M. Alian, Minjel Shah, Momin Mohammad and Ramzi M. Mohammad
Affiliation:
Keywords: Network pharmacology, drug attrition, systems biology, network medicine
Abstract: In the process of drug development, there has been an exceptionally high attrition rate in oncological compounds entering late phases of testing. This has seen a concurrent reduction in approved NCEs (new chemical entities) reaching patients. Network pharmacology has become a valuable tool in understanding the fine details of drug-target interactions as well as painting a more practical picture of phenotype relationships to patients and drugs. By utilizing all the tools achieved through molecular medicine and combining it with high throughput data analysis, interactions and mechanisms can be elucidated and treatments reasonably tailored to patients expressing specific phenotypes (or genotypes) of disease, essentially reigning in the phenomenon of drug attrition.
Export Options
About this article
Cite this article as:
M. Alian Osama, Shah Minjel, Mohammad Momin and M. Mohammad Ramzi, Network Pharmacology: Reigning in Drug Attrition?, Current Drug Discovery Technologies 2013; 10 (2) . https://dx.doi.org/10.2174/1570163811310020008
DOI https://dx.doi.org/10.2174/1570163811310020008 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phase II and Pharmacological Study of Oral Docetaxel Plus Cyclosporin A in Anthracycline Pre-Treated Metastatic Breast Cancer
Current Clinical Pharmacology NSAIDs Induced Regulation of Alternatively Spliced Transcript Isoforms: Possible Role in Cancer and Alzheimer Disease
Current Cancer Drug Targets The Influence of Macrophages and the Tumor Microenvironment on Natural Killer Cells
Current Molecular Medicine Discovery of Lansoprazole and its Unique Pharmacological Properties Independent from Anti-secretory Activity
Current Pharmaceutical Design Malignant Glioma In Vitro Models: On the Utilization of Stem-like Cells
Current Cancer Drug Targets Glioma Therapy: A Novel Insight in the Immunotherapeutic Regime with T11TS/SLFA-3
Central Nervous System Agents in Medicinal Chemistry Therapeutic Exploitation of Apoptosis and Autophagy for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Uptake of [¹⁸F]tetrafluoroborate in MCF-7 Breast Cancer Cells is Induced after Stimulation of the Sodium Iodide Symporter
Current Cancer Drug Targets Inhibitors for Proteins Endowed with Catalytic and Non-Catalytic Activity which Recognize pTyr
Current Medicinal Chemistry Brain Tumor Detection Using Machine Learning and Deep Learning: A Review
Current Medical Imaging Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Cytokine Profile in Patients Infected with Anisakis simplex in Endemic Areas: Dietary Intervention with Polyphenols: A Working Hypothesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot Topic: New Developments in Drug and Vaccine Discoveries (Executive Editor: Aldar S. Bourinbaiar)]
Current Pharmaceutical Design Polymeric Materials and Formulation Technologies for Modified-Release Tablet Development
Mini-Reviews in Medicinal Chemistry Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Novel Anticancer Targets and Drug Discovery in Post Genomic Age
Current Medicinal Chemistry - Anti-Cancer Agents Cancer Stem-Cells Patents in the Context of their Therapeutic Purposes: Exploring the Latest Trends (2011-2015)
Recent Patents on Regenerative Medicine Synthesis, Structure-Activity Relationship and Biological Activity of Acridine Derivatives as Potent MDR-Reversing Agents
Current Medicinal Chemistry Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform
Current Pharmaceutical Design First Total Synthesis of ω-Phenyl Δ6 Fatty Acids and their Leishmanicidal and Anticancer Properties
Current Topics in Medicinal Chemistry